Digital Therapeutics in Oncology Market Research Report, Analysis and Forecast – (2021 – 2028)

Evolving Market Trends in the Digital Therapeutics in Oncology Market 

The Digital Therapeutics in Oncology Market is undergoing a structural transformation, evolving from a niche innovation into a fundamental pillar of cancer care. This evolution is driven by a surge in oncological disease prevalence, increased focus on value-based care models, and a growing need for scalable, cost-efficient, patient-centric solutions. As healthcare systems struggle to accommodate the long-term management of cancer survivors and rising therapy costs, digital therapeutics are emerging as crucial solutions that reduce clinical burden and enhance patient outcomes.

For instance, the global cancer burden is expected to rise to 28.4 million cases annually by 2040, marking a 47% increase from 2020 levels. In such a scenario, the Digital Therapeutics in Oncology Market is well-positioned to meet the expanding need for continuous monitoring, therapy management, and remote patient engagement. Companies are deploying software-based interventions that help patients manage side effects, medication adherence, fatigue, and post-treatment depression—all while reducing dependency on overstretched clinical infrastructure. 

Technological Advancements Catalyzing the Digital Therapeutics in Oncology Market 

A defining force behind the acceleration of the Digital Therapeutics in Oncology Market is the integration of artificial intelligence (AI), real-time analytics, and wearable technologies into digital health platforms. These technologies enable real-time data capture and personalized feedback loops that are vital in oncology, where every deviation in therapy or behavior can significantly affect treatment efficacy.

For example, applications such as Voluntis’ Theraxium Oncology platform use AI-driven algorithms to guide patients through chemotherapy by managing adverse effects in real time. These platforms allow oncologists to adjust treatment protocols dynamically, based on the incoming patient data, reducing emergency visits and improving compliance. Similarly, wearable-integrated platforms such as Biofourmis’ Biovitals are enabling oncologists to detect early signs of treatment toxicity and intervene before critical deterioration occurs.

These technologies are not limited to high-income markets. India and Southeast Asia have seen the introduction of mobile-first oncology DTx platforms that allow underserved populations to access evidence-based behavioral therapies in regional languages, addressing cultural and logistical barriers to care. 

Patient-Centered Care Driving Demand in the Digital Therapeutics in Oncology Market 

Another significant trend in the Digital Therapeutics in Oncology Market is the consumerization of oncology care. Patients, particularly those dealing with chronic or terminal illnesses, are demanding more autonomy, better quality of life, and tools that enable real-time communication with care teams. Digital therapeutics fulfill these expectations by offering on-demand access to validated, protocol-driven therapies that run parallel to hospital-based treatments.

For instance, Kaiku Health, a digital symptom monitoring platform, provides patient-reported outcome (PRO) management for cancer therapies and is integrated into multiple European cancer centers. Such platforms reduce clinician workload while enhancing quality-adjusted life years (QALYs), demonstrating how patient-centered DTx solutions are not merely adjunct tools but vital infrastructure in oncology workflows. 

The Digital Therapeutics in Oncology Market is also tapping into unmet psychosocial needs. Cancer-related anxiety and depression impact nearly 35% of all patients undergoing treatment. DTx applications offering CBT (cognitive-behavioral therapy), mindfulness, and resilience training have reported as much as a 40% reduction in anxiety symptoms when deployed during chemotherapy cycles. This aligns with the broader movement toward holistic, patient-centric oncology models. 

Digital Therapeutics in Oncology Market Size and Commercial Expansion 

The Digital Therapeutics in Oncology Market Size is poised for robust expansion as new reimbursement frameworks and regulatory recognition accelerate commercial adoption. Datavagyanik estimates the market to exceed USD 1.3 billion by 2027, growing at a compound annual growth rate (CAGR) of 20.2% between 2023 and 2027. This growth is primarily led by North America and Europe, where reimbursement for digital oncology solutions is beginning to be formalized. 

For example, in the U.S., Medicare Advantage plans are now experimenting with covering digital symptom trackers and virtual behavioral interventions as part of integrated cancer care models. Germany’s DiGA framework, meanwhile, has approved multiple oncology-focused DTx applications under its statutory insurance scheme, paving the way for broader EU adoption. 

At the commercial level, digital therapeutics companies are forming partnerships with major pharmaceutical players. Roche’s collaboration with Kaiku Health and AstraZeneca’s digital patient support platforms are examples of how pharma is integrating DTx tools into therapy regimens to improve adherence and real-world outcomes, further legitimizing the Digital Therapeutics in Oncology Market within conventional clinical ecosystems. 

Expansion of Application Areas in the Digital Therapeutics in Oncology Market 

While early DTx oncology applications focused on supportive care, the Digital Therapeutics in Oncology Market is rapidly broadening its scope across the full continuum of cancer care—from prevention and diagnosis to survivorship. For example, evidence-based DTx tools for smoking cessation are being deployed in high-risk populations to prevent lung cancer, a leading cause of cancer-related death worldwide.

On the diagnostic front, some platforms are leveraging digital biomarkers and machine learning to identify early symptoms of tumor growth through passive monitoring. Although these applications are in the early stages of regulatory review, pilot results have shown promising accuracy, especially in conditions like melanoma, where early intervention is critical. 

Post-treatment survivorship is another key growth area in the Digital Therapeutics in Oncology Market. Survivors often face a cascade of long-term side effects, such as chronic fatigue, neuropathy, and anxiety. Digital therapeutics tailored to manage survivorship care plans are showing measurable results in patient satisfaction and clinical efficiency. For example, survivor-focused platforms that track nutritional behavior, physical activity, and psychosocial health have reduced hospital readmissions by over 18% in pilot studies. 

Behavioral and Adherence Interventions Leading Market Growth 

Therapeutic non-adherence is one of oncology’s most costly challenges, contributing to suboptimal outcomes and excessive treatment costs. The Digital Therapeutics in Oncology Market is increasingly focused on interventions that improve adherence to complex drug regimens, particularly oral chemotherapies, which are prone to missed doses due to side effects or psychological resistance.

Platforms like OncoHealth and Carevive provide real-time adherence dashboards, enabling care teams to intervene at the first signs of deviation. A study cited by Datavagyanik found that patients using DTx adherence tools had 30% higher medication completion rates compared to control groups. In parallel, these tools capture structured data that enhances population-level analytics and informs future treatment protocols. 

Regional Growth Trends in the Digital Therapeutics in Oncology Market 

The Digital Therapeutics in Oncology Market is witnessing heterogeneous growth patterns across different geographies. North America leads in innovation and reimbursement policy, with major institutions like Mayo Clinic and Memorial Sloan Kettering actively piloting and publishing outcomes from DTx applications. The U.S. remains the highest revenue-generating market, with more than 60% of global oncology DTx startups headquartered in the region.

In contrast, Asia-Pacific represents the fastest-growing market segment. Countries like Japan and South Korea are investing heavily in digital health infrastructure, and oncology-specific DTx tools are being developed with government support. India’s high cancer burden, combined with a digital-first health strategy, is fostering startups like Onco.com that integrate behavioral therapeutics into tele-oncology platforms. 

Meanwhile, European growth is being reinforced by strong regulatory scaffolding. France’s inclusion of digital oncology apps under CNAM reimbursement and Germany’s fast-track DiGA approvals are solidifying Europe’s status as a progressive region in the Digital Therapeutics in Oncology Market. 

Strategic Investments Reshaping the Digital Therapeutics in Oncology Market 

Strategic investments and mergers are also reshaping the Digital Therapeutics in Oncology Market. Venture capital funding in oncology-specific DTx platforms surged by over 80% from 2021 to 2023. Startups like Jasper Health, which focuses on care coordination for oncology patients, have raised multi-million-dollar rounds, indicating strong investor confidence.

Pharmaceutical giants are accelerating digital integration by acquiring or partnering with DTx companies. In 2023, Pfizer’s investment in an AI-powered oncology DTx startup marked one of the largest single funding events in this segment. Such collaborations are geared toward combining pharmacologic therapies with behavioral and digital interventions, a model now termed as “Pharma-DTx hybrid.” 

Geographical Demand Dynamics in the Digital Therapeutics in Oncology Market 

The Digital Therapeutics in Oncology Market is exhibiting distinct regional demand patterns shaped by varying levels of digital health maturity, healthcare infrastructure, and population health needs. The disparity in cancer incidence, access to care, and technological readiness across regions has resulted in differentiated adoption curves for oncology-specific digital therapeutic interventions. 

In North America, the Digital Therapeutics in Oncology demand is being driven by the convergence of high cancer prevalence and advanced digital health ecosystems. The United States alone accounted for over 1.9 million new cancer cases in 2023. With treatment costs soaring and a national shortage of oncologists projected by 2025, digital therapeutics are being rapidly integrated into care delivery models. Datavagyanik identifies North America as contributing to over 45% of global Digital Therapeutics in Oncology Market revenues, owing to large-scale deployments by health systems, insurers, and pharmaceutical partners. Institutions such as the MD Anderson Cancer Center are leveraging remote monitoring DTx tools to support outpatient chemotherapy programs, reducing hospital dependency by up to 22%. 

In Europe, the Digital Therapeutics in Oncology demand is shaped by regulatory momentum and reimbursement reforms. The German DiGA initiative has greenlit several oncology-focused DTx applications for national health coverage. For example, Mika Health’s platform, now reimbursed under Germany’s statutory health insurance, enables patients to track side effects and receive digital coaching. France and the Netherlands are advancing similar pathways, creating an increasingly favorable environment for the Digital Therapeutics in Oncology Market to thrive.

The Asia Pacific region represents the most dynamic growth frontier in the Digital Therapeutics in Oncology Market. Driven by rapidly aging populations, rising cancer incidence, and improved mobile connectivity, countries such as China, Japan, and India are accelerating adoption. In China, mobile-based oncology DTx platforms now serve over 5 million users, often integrated with WeChat-based hospital systems. Japan, with one of the world’s most aged populations, is focusing on DTx applications for geriatric oncology patients, where medication adherence and behavioral interventions can significantly enhance treatment outcomes. India’s National Cancer Grid has started piloting oncology DTx tools to address rural access disparities—highlighting a shift toward decentralizing cancer care through technology.

Latin America and the Middle East are exhibiting slower but rising Digital Therapeutics in Oncology demand, primarily centered on urban centers. In Brazil, partnerships between local digital health startups and private hospitals are testing symptom management apps for breast cancer patients. Similarly, UAE-based platforms are exploring AI-supported behavioral therapy apps targeting post-radiation fatigue in prostate cancer survivors. While these regions currently account for a smaller Digital Therapeutics in Oncology Market Size, Datavagyanik projects double-digit CAGR in the next five years due to improving digital penetration and rising cancer burden. 

Application-Based Segmentation of the Digital Therapeutics in Oncology Market 

The Digital Therapeutics in Oncology Market is segmented across a spectrum of clinical use cases, each addressing a distinct component of the oncology care continuum. The largest and fastest-growing segment is symptom management and supportive care, where digital therapeutics provide real-time interventions to help patients cope with treatment-related adverse events.

For instance, chemotherapy-induced nausea, mucositis, and neuropathy are prevalent across all cancer types. Digital therapeutics such as Voluntis’ OZT Care platform provide algorithm-driven support protocols to manage these symptoms. Studies cited by Datavagyanik show that such platforms can reduce symptom-related emergency department visits by up to 30%, thereby easing systemic healthcare burdens and enhancing patient quality of life.

The second key segment is medication adherence and behavior modification. Oral chemotherapy adherence rates can be as low as 60% without intervention. DTx solutions like Medisafe’s oncology module deploy AI to send personalized reminders, monitor pill intake, and flag non-adherence in real time. Datavagyanik indicates that patients using structured adherence platforms are 1.5x more likely to complete full therapy cycles, significantly improving treatment efficacy and outcomes. 

Mental health and psychosocial support is another critical subsegment. With up to 40% of cancer patients experiencing clinical levels of anxiety or depression, digital therapeutics offering CBT, meditation, and emotional support modules are gaining prominence. Platforms like Blue Note Therapeutics are FDA-designated tools addressing psychological distress in oncology. Datavagyanik notes a 28% improvement in emotional well-being scores among patients who engaged with oncology DTx mental health apps during active treatment. 

Emerging segments in the Digital Therapeutics in Oncology Market include digital rehabilitation for cancer survivors, which provide lifestyle, nutrition, and physical activity guidance post-treatment. Platforms aimed at long-term survivors are also integrating cardiac health, bone density, and metabolic monitoring, especially for breast and prostate cancer patients who face higher risk of chronic comorbidities after therapy. 

Technology-Based Segmentation in the Digital Therapeutics in Oncology Market 

From a technological standpoint, the Digital Therapeutics in Oncology Market is segmented into mobile health applications, wearable-integrated platforms, AI-based analytics tools, and web-based therapeutic interventions. The mobile app segment leads the market due to high smartphone penetration and the ease of delivering interventions remotely.

For example, mobile apps like Belong.Life offer cancer patients AI-based guidance, peer support, and clinician communication in one integrated platform. With over 2 million users globally, it exemplifies the mobile-first approach dominating this space. Wearable technology, while secondary in terms of volume, is rapidly gaining traction. Devices like Apple Watch and Fitbit are now used to track post-chemo fatigue, heart rate variability, and physical activity levels, providing actionable data for both patients and clinicians.

AI and machine learning tools are at the frontier of innovation in the Digital Therapeutics in Oncology Market. Companies are developing predictive models that assess risk of adverse effects, therapy discontinuation, or relapse. For instance, IBM Watson Oncology has piloted machine-learning modules capable of providing treatment recommendations based on EMR data, although adoption has been cautious due to clinical validation requirements. 

Digital Therapeutics in Oncology Market Size and Price Trend Analysis 

As the Digital Therapeutics in Oncology Market Size expands, pricing strategies are evolving to accommodate payer expectations, patient affordability, and regulatory frameworks. The market is bifurcated into two pricing archetypes—subscription-based models for healthcare institutions and freemium-to-premium models for direct-to-patient platforms.

In the institutional segment, oncology centers and health insurers are paying per-patient-per-month (PPPM) fees for integrated DTx platforms. For example, leading platforms like Kaiku Health charge oncology providers based on patient volumes, with fees ranging from USD 10 to USD 35 per user per month depending on feature complexity. Datavagyanik identifies this model as sustainable for health systems where value-based reimbursement is being implemented.

On the consumer side, freemium models dominate. Apps offer basic symptom tracking and reminders for free, while premium services—such as therapy sessions, detailed analytics, and AI-driven coaching—are charged monthly or annually. The average premium oncology DTx subscription ranges from USD 5 to USD 20/month. This pricing strategy has been particularly effective in emerging markets where affordability is a barrier to digital health adoption. 

Wearable-integrated platforms add hardware to the cost equation. Devices such as biosensors and smart bands bundled with DTx software are priced between USD 100 and USD 300, depending on the duration of the subscription and real-time data services included. However, Datavagyanik reports a declining price trend as hardware commoditization and manufacturing scale up, making bundled DTx solutions more accessible globally. 

Price parity across regions remains a challenge. In low- and middle-income countries, affordability is being addressed through public-private partnerships. For example, in India, oncology DTx platforms are being offered at subsidized rates through partnerships with state cancer hospitals, with pricing models as low as USD 1/month to drive penetration. 

Commercial Outlook for the Digital Therapeutics in Oncology Market 

The commercialization of digital therapeutics in oncology is entering a new maturity phase, with strong momentum from both public health systems and private players. Datavagyanik anticipates that over 60% of oncology centers in developed markets will adopt at least one form of DTx platform by 2027. With rising competition, companies are differentiating through clinical evidence, user engagement metrics, and integration capability with electronic health records (EHRs). 

Manufacturers are increasingly focusing on value demonstration—showing quantifiable improvements in treatment adherence, patient-reported outcomes, and cost reductions. For instance, a U.S.-based payer partnership with an oncology DTx provider yielded a 14% reduction in total care costs per cancer patient over 12 months, prompting contract renewal and wider deployment across states. 

 

Key Players in the Digital Therapeutics in Oncology Market 

The Digital Therapeutics in Oncology Market has become a focal point for innovation, with multiple players introducing advanced solutions to address diverse oncology care needs. As demand accelerates for technology-driven interventions, several companies are emerging as leaders through platform-based models, strategic collaborations, and condition-specific digital tools. 

Sidekick Health – Integrated DTx for Oncology Adherence 

Sidekick Health has carved a significant niche in the Digital Therapeutics in Oncology Market by developing personalized, evidence-based DTx solutions focused on treatment adherence and quality of life. Its oncology modules are designed to help patients undergoing chemotherapy manage fatigue, nutrition, hydration, and emotional distress. The platform incorporates gamified behavioral change methods, cognitive behavioral therapy (CBT), and real-time coaching.

Sidekick’s oncology-specific programs are being adopted by health systems and pharmaceutical companies looking to reduce treatment drop-off rates and improve patient engagement. Its market share is rising rapidly, with oncology contributing to a significant portion of the company’s expanding DTx portfolio. 

Jasper Health – Holistic Digital Navigation Platform 

Jasper Health operates a virtual care navigation platform tailored to cancer patients, focusing on both clinical coordination and psychosocial support. The app offers medication reminders, symptom trackers, mood logs, and a secure messaging channel with health coaches. It supports patients from diagnosis through survivorship, making it one of the more comprehensive digital solutions in the Digital Therapeutics in Oncology Market.

The company’s recent expansion across major U.S. cancer centers and employer health plans has strengthened its footprint. Its oncology-specific features and patient-centric design contribute to increasing demand, particularly in outpatient oncology and employer-sponsored care environments. 

Voluntis (Aptar Digital Health) – Oncology Algorithm Automation 

Voluntis, now part of Aptar Digital Health, developed the Theraxium platform—an FDA-cleared digital therapeutic focused on managing cancer therapy side effects such as nausea, mucositis, and pain. Its core strength lies in intelligent symptom triaging and automated intervention protocols, which assist both patients and care teams in real-time decision-making. 

Theraxium has been adopted in partnership models with leading pharmaceutical companies to complement oral chemotherapy and immunotherapy regimens. Its clinical validation and ability to integrate with electronic health records (EHRs) give it a unique advantage in the Digital Therapeutics in Oncology Market, particularly within Europe and North America. 

Kaiku Health – Symptom Monitoring Across Cancer Types 

Kaiku Health offers a digital platform that enables real-time monitoring of patient-reported symptoms and adverse events during cancer treatment. Its technology allows oncology centers to detect deterioration early and intervene proactively, thus improving continuity of care and reducing emergency hospitalizations. 

Kaiku Health’s integration into multiple European hospitals and its adoption by pharmaceutical partners for treatment outcome optimization have positioned it as a strong contender in the Digital Therapeutics in Oncology Market. The platform is widely used across oncology subtypes, including breast, lung, and gastrointestinal cancers. 

Blue Note Therapeutics – Behavioral Health for Cancer 

Specializing in mental health, Blue Note Therapeutics is developing prescription digital therapeutics (PDTs) that target psychological distress among cancer patients. Its lead product, currently in development, focuses on cognitive-behavioral therapy for anxiety, depression, and cancer-related stress. 

With emotional wellbeing becoming a core focus area in cancer care, Blue Note’s targeted solutions are filling a critical gap. Its products are anticipated to gain strong traction as behavioral health becomes more closely integrated into oncology treatment pathways. 

Belong.Life – Community and Navigation in One App 

Belong.Life’s “Beating Cancer Together” app has grown into one of the largest global social and navigation platforms for oncology patients. It combines AI-driven treatment journey mapping with access to oncologists, peer communities, and educational content. The app supports over 2 million users globally, with its oncology segment accounting for the majority of engagement. 

Belong.Life’s unique patient-centric approach—blending social interaction with care planning—makes it a key digital health brand within the Digital Therapeutics in Oncology Market, particularly in patient-initiated DTx segments. 

Estimated Market Positioning of Key Players 

Based on product reach, integration with care ecosystems, and user adoption, companies like Sidekick Health, Voluntis, and Jasper Health currently lead the Digital Therapeutics in Oncology Market in terms of structured deployment in institutional settings. Belong.Life dominates the community-based and direct-to-consumer segment, while Kaiku Health and Blue Note Therapeutics are steadily growing through their evidence-based clinical models.

While exact percentage shares are difficult to quantify due to overlapping categories and private financial data, these top six companies collectively represent the most active drivers of growth and innovation in the Digital Therapeutics in Oncology Market.

Recent Developments in the Digital Therapeutics in Oncology Market 

January 2024 – Sidekick Health Expands Oncology Platform 

Sidekick Health announced a strategic expansion of its oncology modules across two new cancer types—colorectal and lung cancer. These new programs include enhanced AI-based symptom prediction and integrated video coaching. This expansion marks the company’s deeper push into hospital-based digital oncology pathways. 

February 2024 – Kaiku Health Integrates with Pharma Companion Apps 

Kaiku Health entered into new partnerships with pharmaceutical companies to embed its symptom tracking tools within drug-specific companion apps. These integrations will initially focus on breast and prostate cancer treatments, increasing adherence and pharmacovigilance. 

March 2024 – Jasper Health Raises Series B for Oncology Scaling 

Jasper Health closed a Series B funding round to scale its oncology navigation services. The company announced the development of an advanced predictive model that uses machine learning to tailor care plans based on real-time user data, with deployment across five new U.S. healthcare networks. 

April 2024 – Blue Note Therapeutics Enters Clinical Trial Phase II 

Blue Note Therapeutics moved into Phase II clinical trials for its PDT targeting cancer-related anxiety and depression. The study spans multiple cancer centers and is expected to provide key data for regulatory filings in late 2025. 

May 2024 – Belong.Life Launches Real-Time Clinical Trial Matching 

Belong.Life launched a real-time clinical trial matching service embedded within its cancer app, using natural language processing to match patient profiles with global trial databases. The feature is expected to streamline access to emerging therapies and expand the app’s utility in oncology treatment planning.